Markers for different glial cell responses in multiple sclerosis: clinical and pathological correlations

Area of Science:

• Neuroimmunology
• Biomarker Discovery
• Neurological Disorders

Background:

• Multiple sclerosis (MS) progression involves glial activation and gliosis.
• Understanding glial cell responses is crucial for disease management.
• Biomarkers are needed to track disease dynamics and disability.

Purpose of the Study:

• Investigate glial cell biomarkers (S100B, ferritin, GFAP) in relation to MS subtypes and disease dynamics.
• Correlate biomarker levels with patient disability using clinical assessments.
• Validate findings through a post-mortem study of brain tissue.

Main Methods:

• Analyzed cerebrospinal fluid (CSF) and post-mortem brain tissue from MS patients and controls.
• Quantified S100B, ferritin, and glial-fibrillary acidic protein (GFAP) using ELISA.
• Assessed disability with the Ambulation Index (AI), EDSS, and 9-hole PEG test (9HPT).

Main Results:

• S100B levels increased with disease severity (PP to SP to RR MS) and were higher in relapsing-remitting MS.
• Ferritin levels were elevated in secondary progressive MS and throughout all lesion stages.
• GFAP levels correlated significantly with disability measures (AI, EDSS) and ambulation in SP MS.

Conclusions:

• S100B serves as a marker for the relapsing phase of MS, while ferritin indicates ongoing inflammation.
• GFAP is a potential marker for irreversible damage and disability progression in MS.
• These biomarkers offer potential for sensitive outcome measures in MS clinical trials and patient classification.